๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

NITROREDUCTASE: A PRODRUG-ACTIVATING ENZYME FOR CANCER GENE THERAPY

โœ Scribed by Peter F Searle; Ming-Jen Chen; Longqin Hu; Paul R Race; Andrew L Lovering; Jane I Grove; Chris Guise; Mansooreh Jaberipour; Nicholas D James; Vivien Mautner; Lawrence S Young; David J Kerr; Andrew Mountain; Scott A White; Eva I Hyde


Book ID
108937550
Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
317 KB
Volume
31
Category
Article
ISSN
0305-1870

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Prodrug activation enzymes in cancer gen
โœ Manish Aghi; Fred Hochberg; Xandra O. Breakefield ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 202 KB ๐Ÿ‘ 2 views

Among the broad array of genes that have been evaluated for tumor therapy, those encoding prodrug activation enzymes are especially appealing as they directly complement ongoing clinical chemotherapeutic regimes. These enzymes can activate prodrugs that have low inherent toxicity using both bacteria

A novel enediyne prodrug for antibody-di
โœ M.P. Hay; W.R. Wilson; W.A. Denny ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 256 KB

The synthesis of a novel enediyne 2, and its cytotoxicity and activation by the nitroreductase enzyme NR2 from Esherichia coli B, are described. In contrast to closely related analogues, 2 exhibits a 90-fold increase in cytotoxicity against UV4 cells in the presence of the enzyme and NADH, suggestin